A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer

Maria Q. Baggstrom, Yingwei Qi, Marianna Koczywas, Athanassios Argiris, Elizabeth A. Johnson, Michael J. Millward, Sara C. Murphy, Charles Erlichman, Charles M. Rudin, Ramaswamy Govindan

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Background: AT-101 is an oral inhibitor of the antiapoptotic Bcl proteins (Bcl-2, Bcl-XL, Bcl-W, and Mcl-1) and an inducer of the pro-apoptotic proteins noxa and puma. We studied the efficacy of AT-101 in patients with recurrent chemosensitive extensive-stage small cell lung cancer (SCLC). Methods: Patients with recurrent "sensitive" SCLC (defined as no progression during and no disease recurrence <2 months after completion of first-line platinum-based chemotherapy) were eligible. AT-101 was administered 20 mg orally daily for 21 of 28 days each cycle for up to six cycles. The primary end point was the objective response rate. Results: At the time of planned interim evaluation, none of the 14 evaluable patients enrolled in the first stage had any response to therapy, and the study was closed permanently for further accrual. Three patients (21%) achieved stable disease after two cycles of therapy. Grade 3 toxicities included anorexia, fatigue, and nausea/vomiting. Conclusions: AT-101 is not active in patients with recurrent chemosensitive SCLC.

Original languageEnglish (US)
Pages (from-to)1757-1760
Number of pages4
JournalJournal of Thoracic Oncology
Volume6
Issue number10
DOIs
StatePublished - Oct 2011

Fingerprint

Gossypol
Small Cell Lung Carcinoma
Drug Therapy
Puma
Noxae
Apoptosis Regulatory Proteins
Anorexia
Platinum
Nausea
Vomiting
Fatigue
gossypol acetic acid
Recurrence
Therapeutics
Proteins

Keywords

  • AT-101
  • Extensive-stage small cell lung cancer
  • Gossypol

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Baggstrom, M. Q., Qi, Y., Koczywas, M., Argiris, A., Johnson, E. A., Millward, M. J., ... Govindan, R. (2011). A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. Journal of Thoracic Oncology, 6(10), 1757-1760. https://doi.org/10.1097/JTO.0b013e31822e2941

A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. / Baggstrom, Maria Q.; Qi, Yingwei; Koczywas, Marianna; Argiris, Athanassios; Johnson, Elizabeth A.; Millward, Michael J.; Murphy, Sara C.; Erlichman, Charles; Rudin, Charles M.; Govindan, Ramaswamy.

In: Journal of Thoracic Oncology, Vol. 6, No. 10, 10.2011, p. 1757-1760.

Research output: Contribution to journalArticle

Baggstrom, MQ, Qi, Y, Koczywas, M, Argiris, A, Johnson, EA, Millward, MJ, Murphy, SC, Erlichman, C, Rudin, CM & Govindan, R 2011, 'A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer', Journal of Thoracic Oncology, vol. 6, no. 10, pp. 1757-1760. https://doi.org/10.1097/JTO.0b013e31822e2941
Baggstrom, Maria Q. ; Qi, Yingwei ; Koczywas, Marianna ; Argiris, Athanassios ; Johnson, Elizabeth A. ; Millward, Michael J. ; Murphy, Sara C. ; Erlichman, Charles ; Rudin, Charles M. ; Govindan, Ramaswamy. / A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. In: Journal of Thoracic Oncology. 2011 ; Vol. 6, No. 10. pp. 1757-1760.
@article{4c1fea02feea424ea4dd8a2050640bb0,
title = "A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer",
abstract = "Background: AT-101 is an oral inhibitor of the antiapoptotic Bcl proteins (Bcl-2, Bcl-XL, Bcl-W, and Mcl-1) and an inducer of the pro-apoptotic proteins noxa and puma. We studied the efficacy of AT-101 in patients with recurrent chemosensitive extensive-stage small cell lung cancer (SCLC). Methods: Patients with recurrent {"}sensitive{"} SCLC (defined as no progression during and no disease recurrence <2 months after completion of first-line platinum-based chemotherapy) were eligible. AT-101 was administered 20 mg orally daily for 21 of 28 days each cycle for up to six cycles. The primary end point was the objective response rate. Results: At the time of planned interim evaluation, none of the 14 evaluable patients enrolled in the first stage had any response to therapy, and the study was closed permanently for further accrual. Three patients (21{\%}) achieved stable disease after two cycles of therapy. Grade 3 toxicities included anorexia, fatigue, and nausea/vomiting. Conclusions: AT-101 is not active in patients with recurrent chemosensitive SCLC.",
keywords = "AT-101, Extensive-stage small cell lung cancer, Gossypol",
author = "Baggstrom, {Maria Q.} and Yingwei Qi and Marianna Koczywas and Athanassios Argiris and Johnson, {Elizabeth A.} and Millward, {Michael J.} and Murphy, {Sara C.} and Charles Erlichman and Rudin, {Charles M.} and Ramaswamy Govindan",
year = "2011",
month = "10",
doi = "10.1097/JTO.0b013e31822e2941",
language = "English (US)",
volume = "6",
pages = "1757--1760",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "10",

}

TY - JOUR

T1 - A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer

AU - Baggstrom, Maria Q.

AU - Qi, Yingwei

AU - Koczywas, Marianna

AU - Argiris, Athanassios

AU - Johnson, Elizabeth A.

AU - Millward, Michael J.

AU - Murphy, Sara C.

AU - Erlichman, Charles

AU - Rudin, Charles M.

AU - Govindan, Ramaswamy

PY - 2011/10

Y1 - 2011/10

N2 - Background: AT-101 is an oral inhibitor of the antiapoptotic Bcl proteins (Bcl-2, Bcl-XL, Bcl-W, and Mcl-1) and an inducer of the pro-apoptotic proteins noxa and puma. We studied the efficacy of AT-101 in patients with recurrent chemosensitive extensive-stage small cell lung cancer (SCLC). Methods: Patients with recurrent "sensitive" SCLC (defined as no progression during and no disease recurrence <2 months after completion of first-line platinum-based chemotherapy) were eligible. AT-101 was administered 20 mg orally daily for 21 of 28 days each cycle for up to six cycles. The primary end point was the objective response rate. Results: At the time of planned interim evaluation, none of the 14 evaluable patients enrolled in the first stage had any response to therapy, and the study was closed permanently for further accrual. Three patients (21%) achieved stable disease after two cycles of therapy. Grade 3 toxicities included anorexia, fatigue, and nausea/vomiting. Conclusions: AT-101 is not active in patients with recurrent chemosensitive SCLC.

AB - Background: AT-101 is an oral inhibitor of the antiapoptotic Bcl proteins (Bcl-2, Bcl-XL, Bcl-W, and Mcl-1) and an inducer of the pro-apoptotic proteins noxa and puma. We studied the efficacy of AT-101 in patients with recurrent chemosensitive extensive-stage small cell lung cancer (SCLC). Methods: Patients with recurrent "sensitive" SCLC (defined as no progression during and no disease recurrence <2 months after completion of first-line platinum-based chemotherapy) were eligible. AT-101 was administered 20 mg orally daily for 21 of 28 days each cycle for up to six cycles. The primary end point was the objective response rate. Results: At the time of planned interim evaluation, none of the 14 evaluable patients enrolled in the first stage had any response to therapy, and the study was closed permanently for further accrual. Three patients (21%) achieved stable disease after two cycles of therapy. Grade 3 toxicities included anorexia, fatigue, and nausea/vomiting. Conclusions: AT-101 is not active in patients with recurrent chemosensitive SCLC.

KW - AT-101

KW - Extensive-stage small cell lung cancer

KW - Gossypol

UR - http://www.scopus.com/inward/record.url?scp=80052995730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052995730&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e31822e2941

DO - 10.1097/JTO.0b013e31822e2941

M3 - Article

C2 - 21918390

AN - SCOPUS:80052995730

VL - 6

SP - 1757

EP - 1760

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 10

ER -